BioNTech SE has entered a three-year collaboration with Medigene AG to develop immunotherapies against solid tumours using Medigene’s proprietary T cell receptor (TCR) technology. This technology involves engineering a patient’s own T cells in order to display receptors that can recognise specific cancer antigens. Under the agreement, Medigene’s TCR discovery platform will be used in the development of cancer therapies against tumour targets nominated by BioNTech.
